Abstract
Background and aim Environmental factors are strongly implicated in late-onset inflammatory bowel disease. By measuring perfluoroalkyl substances we investigate whether high exposure correlates with late-onset inflammatory bowel disease, and disturbances of the bile acid pool. We further explore the effect of perfluoronoctanoic acid on intestinal barrier function in murine tissue.
Methods Serum levels of perfluoroalkyl substances and bile acids were assessed in matched samples from patients with ulcerative colitis (n = 20) and Crohn’s disease (n = 20) diagnosed at the age of ≥55 years. Blood donors (n = 20), were used as healthy controls. The metabolites were assessed by ultra-performance liquid chromatography coupled to a triple-quadrupole mass spectrometer. Ex vivo exposure of perfluoronoctanoic acid in ileal and colonic murine tissue was assessed with the Ussing Chamber methodology (n = 5).
Results The total level of perfluoroalkyl substances was significantly increased in patients with ulcerative colitis compared to healthy controls or patients with Crohn’s disease (p< 0.05). Ex vivo exposure of 100 μM perfluoronoctanoic acid induced a significantly increased paracellular permeability across ileum (p< 0.05) and an enhanced carbachol-induced ion secretion in colon. The distribution of bile acids as well as the correlation pattern between perfluoroalkyl substances and bile acids differed between patient groups and controls.
Conclusion Our results demonstrate that the levels of perfluoroalkyl substances are increased in patients with late-onset ulcerative colitis and might contribute to the disease by inducing a dysfunctional intestinal barrier or indirectly by interfering with the bile acid metabolism and thereby alter the intestinal barrier function.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by funding from the Faculty of Medicine and Health, Orebro University [grant number: ORU2018/04457 to I.S], Bo Rydin foundation [grant number: F0514 to I.S], Orebro Hospital Research Foundation [Grant number OLL-790011 to J.H] Swedish research council [grant number 2016-05176 to T.H], Formas [grant number. 2019-00869 to T.H and M.O].
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Local Ethics Committee approved the study (Dnr: 2006/245), and all patients as well as external controls gave their written informed consent. All animal procedures and protocols were approved by UC Davis animal care and use committee (IACUC #20072).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The datasets generated during the current study are available from the corresponding author on reasonable request.
